Myogen's Unpopular Ambrisentan Deal with GSK
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 70 (Table of Contents)
Published: 1 Apr-2006
DOI: 10.3833/pdr.v2006.i70.531 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
lt;bgt;Myogenlt;/bgt; and lt;bgt;GlaxoSmithKlinelt;/bgt; (GSK) recently formed a two-part collaboration in the field of pulmonary arterial hypertension (PAH), in which Myogen is licensing to GSK the ex-US commercialisation rights for ambrisentan, which is currently in Phase III development for PAH...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS